Q&A with lead author of the GATE trial
For the first time, a generic version of a disease-modifying therapy for multiple sclerosis (MS) has been studied in a phase 3 trial — and it was found to be equivalent in efficacy, safety and tolerability to its brand-name predecessor. That was the upshot of the GATE trial, published recently in JAMA Neurology, which compared a generic form of glatiramer acetate to the costly branded version of the compound, known as Copaxone®.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
GATE’s lead author, Jeffrey Cohen, MD, Director of Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research (pictured above), recently fielded questions from Medscape about this novel study as part of a Medscape-Cleveland Clinic editorial collaboration. The resulting Q&A, available here, provides Dr. Cohen’s perspectives on the study’s findings and their implications for enhanced affordability and accessibility of effective therapies for MS.
Q&A with Brain Trauma Foundation guideline architect Gregory Hawryluk, MD, PhD
Q&A with newly arrived autoimmune neurology specialist Amy Kunchok, MD
A neurocritical care specialist shares what’s spurring growth of this new evaluation approach
Focused ultrasound offers a newer alternative to deep brain stimulation
Prehabilitation can help improve outcomes after spine surgery
Get ready for central vein sign and optical coherence tomography
How these new drugs fit into practice two years out from their first approvals
A conversation on the state of physiatry with the AAPM&R’s Vice President